Detection of minimal residual disease in adult acute myeloid leukemia via CD25

Abstract Background We detected the expression of CD25 in patients with acute myeloid leukemia (AML) to value whether CD25 could be a promising marker for minimal residual disease (MRD). Methods Two hundred and twenty bone marrow (BM) specimens from 98 adult patients with AML after chemotherapy were detected using flow cytometry. The expression of CD25 was compared between MRD positive and negative subgroups. Results About 38% of patients with MRD were positive for CD25. The mean percentage of CD25-positive cell subpopulation was 58.68% relative to the whole MRD cluster (0.05%-100%). The mean fluorescence index ratio (MFIR) of CD25 in these cell subpopulations was approximately13-fold greater than that in normal myeloblasts. The detection sensitivity of CD25 was as high as 10 -4 . CD25 was also expressed on non-leukemic stem cells that were positive for CD34 and CD38. Conclusion CD25, as assessed by flow cytometry, is a promising marker for MRD in patients with AML.

Download Full-text

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

Cancer ◽

10.1002/cncr.30361 ◽

2016 ◽

Vol 123 (3) ◽

pp. 426-435 ◽

Cited By ~ 28

Author(s):

Farhad Ravandi ◽

Jeffrey Jorgensen ◽

Gautam Borthakur ◽

Elias Jabbour ◽

Tapan Kadia ◽

...

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Multiparameter Flow Cytometry ◽

Younger Patients ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia

American Journal of Clinical Pathology ◽

10.1309/ajcp5tsd3dzxflcx ◽

2009 ◽

Vol 131 (1) ◽

pp. 16-26 ◽

Cited By ~ 84

Author(s):

Adhra Al-Mawali ◽

David Gillis ◽

Ian Lewis

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Multiparameter Flow Cytometry ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

Acute Myeloid Leukemia: Diagnosis and Minimal Residual Disease Detection by Flow Cytometry

Manual of Molecular and Clinical Laboratory Immunology ◽

10.1128/9781555818722.ch22 ◽

2016 ◽

pp. 217-225

Author(s):

Brent Wood ◽

Lori Soma

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Disease Detection ◽

Minimal Residual Disease Detection ◽

Leukemia Diagnosis ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets

Leukemia Research ◽

10.1016/j.leukres.2011.11.020 ◽

2012 ◽

Vol 36 (4) ◽

pp. 401-406 ◽

Cited By ~ 27

Author(s):

Giovanni Rossi ◽

Maria Marta Minervini ◽

Angelo Michele Carella ◽

Chiara de Waure ◽

Francesco di Nardo ◽

...

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Molecular Targets ◽

Multiparameter Flow Cytometry ◽

Rna Quantification ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

Leukemia ◽

10.1038/leu.2016.46 ◽

2016 ◽

Vol 30 (7) ◽

pp. 1456-1464 ◽

Cited By ~ 78

Author(s):

Y Zhou ◽

M Othus ◽

D Araki ◽

B L Wood ◽

J P Radich ◽

...

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Multiparameter Flow Cytometry ◽

Post Transplant ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia

Annals of Hematology ◽

10.1007/s00277-019-03861-1 ◽

2019 ◽

Vol 99 (1) ◽

pp. 73-82 ◽

Cited By ~ 3

Author(s):

Meng-Ge Gao ◽

Guo-Rui Ruan ◽

Ying-Jun Chang ◽

Yan-Rong Liu ◽

Ya-Zhen Qin ◽

...

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Quantitative Pcr ◽

Predictive Value ◽

Myeloid Leukemia ◽

Residual Disease ◽

Real Time Quantitative Pcr ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Yearbook of Oncology ◽

10.1016/j.yonc.2011.09.001 ◽

2011 ◽

Vol 2011 ◽

pp. 153-154

Author(s):

R.J. Arceci

Keyword(s):

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Minimal Residual Disease ◽

Cell Transplantation ◽

Myeloid Leukemia ◽

Hematopoietic Cell Transplantation ◽

Residual Disease ◽

Multiparametric Flow Cytometry ◽

Minimal Residual ◽

Acute Myeloid

Download Full-text

Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia

Blood ◽

10.1182/blood.v124.21.1015.1015 ◽

2014 ◽

Vol 124 (21) ◽

pp. 1015-1015

Author(s):

Pramod Pinnamaneni ◽

Jeffrey L. Jorgensen ◽

Hagop M. Kantarjian ◽

Elias Jabbour ◽

Sherry R. Pierce ◽

...

Keyword(s):

Bone Marrow ◽

Flow Cytometry ◽

Acute Myeloid Leukemia ◽

Complete Remission ◽

Minimal Residual Disease ◽

Myeloid Leukemia ◽

Residual Disease ◽

Response To Therapy ◽

Minimal Residual ◽

Acute Myeloid

Abstract Purpose – To determine the value of Minimal Residual Disease (MRD) assessed by Multi-parameter Flow Cytometry (MFC) after achieving initial response to therapy, in predicting outcome in patients with acute myeloid leukemia (AML) Methods – We investigated the predictive value of MRD assessment by MFC in 191 patients with newly diagnosed AML treated between February 2010 and April 2014 at our institution who had available MRD assessment. MRD by MFC was assessed using an 8-color panel containing 19 distinct markers, on bone marrow specimens obtained at the time of achievement of CR and at approximately 30 days and 90 days after achieving CR. Residual leukemic blasts were identified based on phenotypic differences from normal myelomonocytic precursors. Sensitivity was estimated at 0.1% in most cases, with maximum achievable sensitivity of 0.01%, depending on the leukemic phenotype. Results – Of the 191 patients, 167 (87%) achieved complete remission (CR) or CR without platelet recovery (CRp). Their median age was 58 years (Range, 17-85). 84 (44%) were older than 60 years. Median WBC at presentation was 3.2 x 109/L(Range, 0.5-100.2 x 109/L) and median bone marrow blast percentage was 43% (Range, 11-96%). Cytogenetics was favorable risk in 4 (2%), intermediate risk in130 (68%) and adverse risk in 57 (30%). Treatment included cytarabine plus anthracycline in 170 (89%) and hypomethylating agents-based strategies in 21 (11%). 48 patients had available samples at 30 days post CR and 32 (67%) became MRD negative. Achieving MRD negative status was associated with a statistically significant improvement in CR duration (p=0.02) and overall survival (OS) (p=0.0005). 56 patients were evaluated for MRD status at 90 days and 45 (80%) were negative. Again, achieving MRD negative status was associated with a significant improvement in CR duration (p=0.002) and OS (p=0.0009). Conclusion – Achieving MRD negative status by MFC at 30 and 90 days post CR is associated with an improved outcome in patients with AML Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.

Download Full-text